Vicarious Surgical Approves Liquidation After Failed Robot Development
Vicarious Surgical has received shareholder approval to wind down and liquidate its business after years of delays in developing a single-port surgical robot. The company, which raised over $425 million before going public via a SPAC merger valued at $1.1 billion, failed to secure regulatory authorization for its device.
Topics: FDA approval delays liquidation robotic surgery SPAC merger